RU2013129748A - Способы лечения заболеваний сетчатки - Google Patents
Способы лечения заболеваний сетчатки Download PDFInfo
- Publication number
- RU2013129748A RU2013129748A RU2013129748/15A RU2013129748A RU2013129748A RU 2013129748 A RU2013129748 A RU 2013129748A RU 2013129748/15 A RU2013129748/15 A RU 2013129748/15A RU 2013129748 A RU2013129748 A RU 2013129748A RU 2013129748 A RU2013129748 A RU 2013129748A
- Authority
- RU
- Russia
- Prior art keywords
- retinal
- disease
- compound
- acute
- retinal pigment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 13
- 201000010099 disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 208000017442 Retinal disease Diseases 0.000 claims abstract 8
- 230000001154 acute effect Effects 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims abstract 8
- 206010010356 Congenital anomaly Diseases 0.000 claims abstract 4
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims abstract 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims abstract 4
- 208000027073 Stargardt disease Diseases 0.000 claims abstract 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims abstract 4
- 201000008615 cone dystrophy Diseases 0.000 claims abstract 4
- 208000011325 dry age related macular degeneration Diseases 0.000 claims abstract 4
- 230000002207 retinal effect Effects 0.000 claims abstract 4
- 239000000790 retinal pigment Substances 0.000 claims abstract 4
- 206010020880 Hypertrophy Diseases 0.000 claims abstract 3
- 208000001344 Macular Edema Diseases 0.000 claims abstract 2
- 206010025415 Macular oedema Diseases 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 206010038848 Retinal detachment Diseases 0.000 claims abstract 2
- 206010057430 Retinal injury Diseases 0.000 claims abstract 2
- 208000016624 Retinal neoplasm Diseases 0.000 claims abstract 2
- 238000002347 injection Methods 0.000 claims abstract 2
- 239000007924 injection Substances 0.000 claims abstract 2
- 201000010230 macular retinal edema Diseases 0.000 claims abstract 2
- 230000036542 oxidative stress Effects 0.000 claims abstract 2
- 239000000049 pigment Substances 0.000 claims abstract 2
- 230000003169 placental effect Effects 0.000 claims abstract 2
- 230000004264 retinal detachment Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 210000001525 retina Anatomy 0.000 abstract 1
- KIAIFXWRJNFSLK-UHFFFAOYSA-N Cc1cc(C(N(CC2)CC[N+]2(C)O)=Nc(cccc2)c2N2)c2[s]1 Chemical compound Cc1cc(C(N(CC2)CC[N+]2(C)O)=Nc(cccc2)c2N2)c2[s]1 KIAIFXWRJNFSLK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41966010P | 2010-12-03 | 2010-12-03 | |
| US61/419,660 | 2010-12-03 | ||
| PCT/US2011/061370 WO2012074788A1 (en) | 2010-12-03 | 2011-11-18 | Methods for treating diseases of the retina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013129748A true RU2013129748A (ru) | 2015-01-10 |
Family
ID=45507856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013129748/15A RU2013129748A (ru) | 2010-12-03 | 2011-11-18 | Способы лечения заболеваний сетчатки |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9018202B2 (https=) |
| EP (1) | EP2646034A1 (https=) |
| JP (1) | JP2013544838A (https=) |
| KR (1) | KR20130122958A (https=) |
| CN (1) | CN103327981A (https=) |
| AU (1) | AU2011336976A1 (https=) |
| BR (1) | BR112013013636A2 (https=) |
| CA (1) | CA2819616A1 (https=) |
| RU (1) | RU2013129748A (https=) |
| WO (1) | WO2012074788A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| JP6864327B2 (ja) | 2017-07-06 | 2021-04-28 | 山田 健一 | 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法 |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| EP3919052A4 (en) * | 2019-01-09 | 2022-10-05 | Fuso Pharmaceutical Industries, Ltd. | Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases |
| US20250170143A1 (en) * | 2022-04-14 | 2025-05-29 | Mayo Foundation For Medical Education And Research | Methods of treating ocular fibrotic pathologies |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1004520A1 (en) | 1992-05-13 | 1998-11-27 | Novartis Ag | Ophthalmic compositions containing a cyclosporin |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| US5631250A (en) | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
| US5744468A (en) * | 1996-10-23 | 1998-04-28 | Tong-Ho Lin | Hypotensive intraocular pressure activity of clozapine and sulpiride |
| JPH10175865A (ja) * | 1996-12-11 | 1998-06-30 | Towa Rin | 抗眼圧活性製剤 |
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| JP2002530340A (ja) * | 1998-11-23 | 2002-09-17 | セプラコール， インク． | オランザピン−ｎ−オキサイドを含む医薬組成物 |
| DE10206941A1 (de) | 2002-02-19 | 2003-09-25 | Goetz Nowak | Neue Arzneimittel |
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
| WO2004103263A2 (en) | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US20060035887A1 (en) | 2004-07-02 | 2006-02-16 | Dr. Reddy's Laboratories Limited | Process for preparing olanzapine |
| AU2005271513A1 (en) * | 2004-08-05 | 2006-02-16 | Acadia Pharmaceuticals Inc. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| CN101437478A (zh) * | 2004-10-04 | 2009-05-20 | Qlt美国有限公司 | 聚合送递制剂的眼部送递 |
| MX2007003789A (es) | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| CN101711236B (zh) * | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
-
2011
- 2011-11-16 US US13/298,028 patent/US9018202B2/en active Active
- 2011-11-18 WO PCT/US2011/061370 patent/WO2012074788A1/en not_active Ceased
- 2011-11-18 CA CA 2819616 patent/CA2819616A1/en not_active Abandoned
- 2011-11-18 JP JP2013542043A patent/JP2013544838A/ja active Pending
- 2011-11-18 KR KR20137017036A patent/KR20130122958A/ko not_active Ceased
- 2011-11-18 BR BR112013013636A patent/BR112013013636A2/pt not_active IP Right Cessation
- 2011-11-18 EP EP11810917.2A patent/EP2646034A1/en not_active Withdrawn
- 2011-11-18 RU RU2013129748/15A patent/RU2013129748A/ru not_active Application Discontinuation
- 2011-11-18 CN CN2011800652550A patent/CN103327981A/zh active Pending
- 2011-11-18 AU AU2011336976A patent/AU2011336976A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/696,789 patent/US9561234B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103327981A (zh) | 2013-09-25 |
| US9018202B2 (en) | 2015-04-28 |
| CA2819616A1 (en) | 2012-06-07 |
| AU2011336976A1 (en) | 2013-07-11 |
| JP2013544838A (ja) | 2013-12-19 |
| US9561234B2 (en) | 2017-02-07 |
| BR112013013636A2 (pt) | 2016-11-08 |
| EP2646034A1 (en) | 2013-10-09 |
| WO2012074788A1 (en) | 2012-06-07 |
| KR20130122958A (ko) | 2013-11-11 |
| US20150290215A1 (en) | 2015-10-15 |
| US20120142675A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaur et al. | Blood–retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management | |
| RU2013129748A (ru) | Способы лечения заболеваний сетчатки | |
| EA201100654A1 (ru) | Соединения для лечения офтальмологических заболеваний и расстройств | |
| MX361520B (es) | Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas. | |
| PH12012502079A1 (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| PH12015501208A1 (en) | Amine derivative compounds for treating ophthalmic diseases and disorders | |
| EA201690066A1 (ru) | Соединения пиримидиндиона | |
| WO2010028088A3 (en) | Sulfur-linked compounds for treating opthalmic diseases and disorders | |
| RU2009144142A (ru) | Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента | |
| EP3932907A3 (en) | Dextromethorphan analogs and combinations of deuterated dextromethorphan and nortriptyline for use in treating agitation and/or aggression | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| WO2020099925A3 (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
| WO2011137344A3 (en) | Anti-s1p antibody treatment of patients with ocular disease | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| HRP20190561T1 (hr) | Postupci liječenja bolesti oka povezanih s upalom i vaskularnom proliferacijom | |
| WO2019210320A3 (en) | Methods and compositions to stimulate retinal regeneration | |
| JP2013544838A5 (https=) | ||
| JP2015519398A5 (https=) | ||
| EP4365299A3 (en) | Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal disease | |
| WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| MY205498A (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| NZ622403A (en) | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method | |
| JP2011513316A5 (https=) | ||
| RU2014106328A (ru) | Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20141119 |